Introgen Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics

INGN 6.950

-2.0%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (278)	4/19/2005 1:07:59 AM
From: zeta1961	Read Replies (2) of 802

>Introgen Therapeutics initiated with "strong buy" [from YMB] Monday, April 18, 2005 6:52:09 AM ET Adams Harkness NEW YORK, April 18 - Analysts at Adams Harkness initiate coverage of Introgen Therapeutics Inc (INGN.NAS) with a "strong buy" rating. The 12-month target price is set to $18. In a research note published this morning, the analysts mention that the company is in the process of conducting two Phase III trials using Advexin, for head and neck cancer. Introgen Therapeutics has also initiated the BLA filing, which is likely to be completed by the end of 2005, the analysts say. The company could also benefit from the delay in the filing of Ebitux, for head and neck cancer, by Imclone and Brystol-Myers.<<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next